TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02791945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT00094042
Drug: Iron Supplement, 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02688907
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first \& second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
Study: NCT02640157
Drug: ABT-493/ABT-530
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-493 coformulated with ABT-530
Study: NCT01931150
Drug: oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03451760
Drug: Feru-guard 100M
Normalized name: Clinda-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feru-guard is a dietary supplement commercially available in Japan in the form of a 1.5 g instant powder packet that is sold in health clinics and directly by Glovia Co. Ltd to patients on doctor's recommendation. The current study will use Feru-guard in the form of a 280 mg hard gel capsule that contains the same amount of the active ingredients (ferulic acid and Angelica archangelica) as the 1.5 g packets. In order to conduct a double-blind, placebo-controlled trial, Feru-guard is contained in opaque, hard gel capsules which allows for better matching of characteristics and improved blinding than studies using powder. Feru-guard will be supplied by Glovia, Co. Ltd., in Tokyo, Japan.
Study: NCT01213160
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: film coated tablet, PO, twice daily
Study: NCT00723021
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x placebo tablets + placebo oral dispersion, single dose.
Study: NCT01502020
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
Study: NCT04349761
Drug: MyMD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isomyosamine 5mg capsules
Study: NCT04349761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00352911
Drug: Placebo for VGX-410 (Mifepristone)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00087178
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Study: NCT00087178
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
Study: NCT04079790
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing unit dose of placebo matching of gepotidacin will be administered orally with 240 mL of water.
Study: NCT02715908
Drug: LBEC0101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50mg
Study: NCT02053311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04374565
Drug: High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathogen reduced SARS-CoV-2 convalescent plasma (1-2 units; \~200 mL each for a total of 200-400mls) given preferably in one day, but allowable to be given over 2 days if clinical circumstances delay infusions in 1 day), with titer to be determined after the unit has been infused.
Study: NCT02647047
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
Study: NCT02647047
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
Study: NCT02647047
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
Study: NCT00381277
Drug: Gatorade
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01389427
Drug: Torisel dose 15 mg and R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 15 mg and R-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 15 mg and R-DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 50 mg and R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 75 mg and R-CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 50 mg and R-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 75 mg and R-FC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel dose 50 mg and R-DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT01389427
Drug: Torisel 75 mg and R-DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
Study: NCT00109382
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02910739
Drug: MK-8931
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8931 40 mg
Study: NCT00826839
Drug: Oral contraceptive pill and microdose lupron
Normalized name: Desogen (contraceptive) Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
Study: NCT02482077
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
Study: NCT00826839
Drug: E2 patch/antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.~Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses.
Study: NCT02179645
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02179645
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220103
Drug: epirubicin, capecitabine, cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04182919
Drug: Phlai
Normalized name: Mycobacterium phlei
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each capsule contains 4 mg compound D. Using orally in the evening everyday in 4 weeks
Study: NCT03635593
Drug: CBD+THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to CBD+THC 10mg (CBD 5mg + THC) for 12 weeks. Participants will start with 1, 10mg CBD+THC (5mg+5mg) capsule per day and self- titrate up to 8, 10mg CBD+THC (5mg+5mg) capsules to a maximum of 80mg (40mg CBD + 40mg THC) per day as needed.
Study: NCT04182919
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Like Phlai capsule extract : :PVP K30, Calcium carbonate, Dibasic calcium phosphate, Sodium starch glycolate, Colloidal silicon dioxide, Ethanol 96%, Purified water, Magnesium stearate. Not having compound D. Using orally in the evening everyday in 4 weeks
Study: NCT01482559
Drug: Dopamine hydrochloride
Normalized name: Dopamine Hydrochloride
DrugBank: Dopamine (DB00988)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Study: NCT01482559
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
Study: NCT04643886
Drug: GEM103
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological
Study: NCT02585440
Drug: CMX157
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT02585440
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet
Study: NCT01072591
Drug: MEDI-578
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion, once
Study: NCT01072591
Drug: Placebo for MEDI-578
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion, once
Study: NCT02953548
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT01023178
Drug: 17beta Estradiol
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pill given daily at increasing doses every 6 months for 18 months.
Study: NCT01023178
Drug: 17Beta Estradiol - transdermal
Normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
Study: NCT00125281
Drug: S-adenosyl-methionine (SAMe) capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04585776
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT00911287
Drug: Oxymorphone extended release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
Study: NCT01108107
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
Study: NCT05017844
Drug: KSR-001-04
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop to both eyes four times a day for 12 weeks
Study: NCT00518375
Drug: Rapamune® (Sirolimus)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518375
Drug: Neoral® (Cyclosporine)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00518375
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left up to local practice but steroids are typically used perioperatively
Study: NCT00791531
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate 5mg once daily for 5 consecutive days
Study: NCT05017844
Drug: KSR-001-02
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop to both eyes four times a day for 12 weeks
Study: NCT05017844
Drug: KSR-001-03
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop to both eyes four times a day for 12 weeks
Study: NCT00680784
Drug: HKT-500 Ketoprofen Topical Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HKT-500 Ketoprofen Topical Patch
Study: NCT00824447
Drug: Oralgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: allergen solution sublingually
Study: NCT03955549
Drug: Treatment As Usual (TAU)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) consists of psychiatric management by a clinical team including at least one psychiatrist and one psychologist. Treatment involves antipsychotic medication, regular office-based contacts with the clinical team for treatment monitoring, recreational group activities, and unstructured psycho-educational groups. Participants in the interventional groups also will receive TAU.~Medications: In order to standardize treatment, Risperidone (Risperdal ) will be used as the antipsychotic medication in all three groups with a dose up to 6-8 milligrams according to clinical severity. The same dose will be used for 1 month prior to starting interventions). In case of occurrence of mild extrapyramidal symptoms associated with high doses of risperidone, an anticholinergic drug (Benztropine) might be used.
Study: NCT03055936
Drug: Levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa 50 mg or 100 mg or 150 mg
Study: NCT03055845
Drug: STA363
Approvals — FDA: no, EMA: no, PMDA: no
Description: STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
Study: NCT03055845
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
Study: NCT00688103
Drug: ETN+MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
Study: NCT02904031
Drug: l-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01924234
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01047423
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg encapsulated once daily for 12 weeks
Study: NCT01047423
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encapsulated oral once daily for 12 weeks
Study: NCT01871285
Drug: Placebo film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo buccal film
Study: NCT01871285
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
Study: NCT03444584
Drug: MEDI0382
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dose of MEDI0382 (titrated up from 100 μg for 7 days to 200 μg for 7 days and to 300 μg for 14 days).
Study: NCT03444584
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous dose of placebo matched to MEDI0382.
Study: NCT03444584
Drug: Dapaglifozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of dapaglifozin 10 mg tablet.
Study: NCT02711072
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
Study: NCT02711072
Drug: infiltration group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
Study: NCT01461616
Drug: NPH
Normalized name: ZENPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: equal doses of NPH insulin, insulin Detemir and insulin glargine injection
Study: NCT02542969
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02542969
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02542969
Drug: MGL-3196
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03675724
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01005771
Drug: GF-001001-00
Approvals — FDA: no, EMA: no, PMDA: no
Description: GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
Study: NCT01005771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT03878082
Drug: IVPCA
Normalized name: Intravenous Patient-Controlled Analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: pain control with IVPCA
Study: NCT00691405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation solution BID
Study: NCT00691405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhalation solution QD
Study: NCT00238524
Drug: SPM 927
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03715582
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills of masking drug - placebo
Study: NCT00835718
Drug: Comparator: MK0594 5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
Study: NCT00835718
Drug: Comparator: MK0594 1 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Study: NCT00835718
Drug: Comparator: MK0594 1 mg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
Study: NCT00835718
Drug: Comparator: Placebo to MK0594
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
Study: NCT03595449
Drug: Surgilube
Normalized name: Surgilube
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgilube (placebo) applied during Mohs surgery
Study: NCT00433459
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug is used in first line treatment in combination (COPP or COPDAC)
Study: NCT00433459
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
Study: NCT00121199
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00121199
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02875678
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose matching placebo
Study: NCT01256476
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg once daily (QD)
Study: NCT01685203
Drug: ABT-450/r
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet; ABT-450; Capsule; ritonavir
Study: NCT01685203
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT03212599
Drug: Disulfiram
Normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
Study: NCT02669511
Drug: PQR309
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral PQR309, 80mg or 60mg daily or intermittent dosing
Study: NCT02293148
Drug: GSK1278863 75 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study: NCT02293148
Drug: GSK1278863 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
Study: NCT02293148
Drug: Placebo matching GSK1278863
Approvals — FDA: no, EMA: no, PMDA: no
Description: A round, biconvex, white film coated tablet as matching placebo for GSK1278863
Study: NCT02315352
Drug: Cesol®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cesol® tablet at a dose of 150 mg crushed in water
Study: NCT00947557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral administration once daily on background of glimepiride with or without metformin
Study: NCT00306696
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 75 mg oral dose (prepared solution), given once
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 150 mg oral dose (prepared solution), given once
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 300 mg oral dose (prepared solution), given once
Study: NCT00793000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match 750 mg oral dose (prepared solution), given once
Study: NCT03081208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dispersible tablets for single oral administration
Study: NCT03660943
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving Placebo Injection
Study: NCT03660943
Drug: CNTX-4975-05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving CNTX-4975-05 Injection